Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Kiniciti
Deal Size : $60.0 million
Deal Type : Partnership
Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings
Details : The transaction gives Kiniciti a control stake in Ncardia to support growth and enhance capabilities spanning discovery to clinical programs to manufacturing of human-induced pluripotent stem cell-based solutions (iPSC).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Kiniciti
Deal Size : $60.0 million
Deal Type : Partnership
Lead Product(s) : Cardiomyocytes
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Bluerock gains access to Ncardia’s large-scale production processes and intellectual property for the production of iPSC-derived cardiomyocytes for therapeutic use.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Cardiomyocytes
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration